CY1111114T1 - Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις - Google Patents

Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις

Info

Publication number
CY1111114T1
CY1111114T1 CY20111100056T CY111100056T CY1111114T1 CY 1111114 T1 CY1111114 T1 CY 1111114T1 CY 20111100056 T CY20111100056 T CY 20111100056T CY 111100056 T CY111100056 T CY 111100056T CY 1111114 T1 CY1111114 T1 CY 1111114T1
Authority
CY
Cyprus
Prior art keywords
antigonic
immunizable
mining
compositions
microphone
Prior art date
Application number
CY20111100056T
Other languages
Greek (el)
English (en)
Inventor
Mariagrazia Pizza
Marzia Monica Giuliani
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1111114T1 publication Critical patent/CY1111114T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20111100056T 2001-12-04 2011-01-18 Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις CY1111114T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
EP02788442A EP1448230B1 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
CY1111114T1 true CY1111114T1 (el) 2015-06-11

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100056T CY1111114T1 (el) 2001-12-04 2011-01-18 Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις

Country Status (11)

Country Link
US (2) US20060008476A1 (https=)
EP (1) EP1448230B1 (https=)
JP (2) JP4414226B2 (https=)
AP (1) AP2004003074A0 (https=)
AT (1) ATE485055T1 (https=)
AU (1) AU2002353417A1 (https=)
CA (1) CA2468935C (https=)
CY (1) CY1111114T1 (https=)
DE (1) DE60238075D1 (https=)
GB (1) GB0129007D0 (https=)
WO (1) WO2003047619A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
KR100898648B1 (ko) * 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN103357002A (zh) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 rLP2086 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012059593A1 (en) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2019410099A1 (en) * 2018-12-21 2021-07-15 Griffith University Compositions, methods and uses for eliciting an immune response
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20220348645A1 (en) * 2019-10-01 2022-11-03 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CN1263854C (zh) * 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
ATE378066T1 (de) * 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
EP1448230A2 (en) 2004-08-25
GB0129007D0 (en) 2002-01-23
DE60238075D1 (de) 2010-12-02
US20100233205A1 (en) 2010-09-16
CA2468935C (en) 2013-02-05
WO2003047619A2 (en) 2003-06-12
JP4414226B2 (ja) 2010-02-10
EP1448230B1 (en) 2010-10-20
AU2002353417A1 (en) 2003-06-17
JP2005511662A (ja) 2005-04-28
ATE485055T1 (de) 2010-11-15
AP2004003074A0 (en) 2004-06-30
JP2009155344A (ja) 2009-07-16
US20060008476A1 (en) 2006-01-12
CA2468935A1 (en) 2003-06-12
WO2003047619A3 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
CY1111114T1 (el) Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
CY1119106T1 (el) Αντισωματα εναντι masp-2
ATE414535T1 (de) Trägerproteine für impfstoffe
CY1108549T1 (el) Συνθετικες μεθοδοι για απλιδινη και νεα κατα του ογκου παραγωγα, μεθοδοι κατασκευης και χρησης αυτων
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
CY1109683T1 (el) Αντιγονα του streptococcus pyogenes
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
PL411824A1 (pl) Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
ATE355104T1 (de) Haarbehandlungsmittel
DE50310977D1 (de) Kompaktiertes menthol
ITVA20020024A1 (it) Prodotti per l'edilizia a base di idrossialchilguaro idrofobizzato purificato
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
TR200003467T2 (tr) Neisseria meningitidis antijenik polipeptidler, mütekabil polinükleotidler ve koruyucu antikorlar
DE60209359D1 (de) Lösungsmittelverklebungsverfahren
ITPN20020022A1 (it) Motore lineare e compressore azionato da detto motore.
BRPI0416201A (pt) métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis
WO2006063028A3 (en) Immunostimulatory compositions and uses thereof
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.